Coherus Oncology reported second quarter 2026 financial results with net revenue of $14.3 million, a 37% increase from the prior year period, driven by LOQTORZI sales of $13.6 million. The company posted a GAAP net loss from continuing operations of $33.3 million, or $(0.22) per diluted share, compared to a $44.9 million loss in Q2 2025. Cash and marketable securities stood at $105.3 million as of June 30, 2026. Pipeline updates included completed enrollment for casdozokitug in hepatocellular carcinoma and tagmokitug in head and neck cancer, with initial data readouts expected in the second half of 2026. Coherus Oncology is a commercial-stage biopharmaceutical company focused on developing and marketing innovative oncology therapies.
